Business, energy, technology, markets and global industry news from Business News Today

HER3

PharmaDeviceNews HER3
Akeso has dosed the first patient in a Phase Ib/II study evaluating the HER3 antibody-drug conjugate AK138D1 with ivonescimab in advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC

Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.

Read More
Representative image of a bispecific antibody-drug conjugate in a cancer research setting, illustrating the science behind CStone Pharmaceuticals’ AACR 2026 update on CS5007, CS5006, and CS5008 oncology pipeline candidates.
Pharma & Biotech

Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update

CStone Pharmaceuticals unveiled three ADC programs at AACR 2026. Read what CS5007, CS5006, and CS5008 could mean for oncology development.

Read More